Claim Missing Document
Check
Articles

Found 2 Documents
Search

Primary Pulmonary Leiomyosarcoma : an Extremely Rare, Difficult-to-Manage Case of Lung Cancer Binharyanto, Adlan Pratama Binharyanto; Ngakan Putu Parsama Putra; Ungky Agus Setyawan; Dini Rachma Erawati; Hendy Setyo Yudhanto
Malang Respiratory Journal Vol. 5 No. 2 (2023): September Edition
Publisher : Universitaas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mrj.2023.005.02.05

Abstract

Background: Primary Pulmonary Leiomyosarcoma (PPL) known as <0.5% of total lung cancer. Histopathological examinations are the pillars of PPL diagnosis as clinical manifestations and radiological features are usually not specific. Treatments of PPL include surgical resection, radiotherapy, and chemotherapy. Case Illustration: A 51-year-old male, smoker, with a productive cough for 2 weeks, accompanied by chest pain, weight loss, and loss of appetite. Imaging studies showed a solid mass in the right lung, which was confirmed through bronchoscopy, cytology, histology, and immunohistochemistry evaluations. Bronchoscopy showed an intraluminal mass in the right main bronchus suggesting malignancy. Immunohistochemistry of Desmin and Smooth Muscle Actin, which were positive, confirmed the diagnosis of PPL of the right lung stage T4N1M1a IVA. Discussion: Surgical resection is the gold standard treatment for PPL whose clinical conditions and tumor spread still allowed for safe operation. Surgical resection did not undergo because already in stage IVA. Radiotherapy and chemotherapy can be added for patients who are unable to have surgery. There are no guidelines regarding chemotherapeutic regimens that are recommended for PPL. Cisplatin/carboplatin and etoposide are two chemotherapeutic agents that are commonly used in other variants of lung cancer. Cisplatin is successful in 5-23% of patients and etoposide is successful in 8%. Doxorubicin and ifosfamide are usually used for soft tissue sarcoma too. After administration of 4 cycles of carboplatin/etoposide, a chest CT scan with contrast recist shows the progression of PPL. Conclusion: Carboplatin and etoposide have been long used as therapy for lung cancer. Currently, available literature shows that their effectiveness in PPL is still considered low. Nevertheless, more studies are needed to further explore the possibilities of using carboplatin and etoposide in PPL patients. Keywords: chemotherapy, lung cancer, primary pulmonary leiomyosarcoma
Differences in Serum Soluble Cluster of Differentiation 163 levels and Monocyte Lymphocyte Ratio between Drug-Resistant and Drug-Sensitive Lung Tuberculosis Nuansa Paramita; Ngakan Putu Parsama Putra; Susanthy Djajalaksana; Rezki Tantular; Ani Budi Astuti
Jurnal Respirologi Indonesia Vol 46 No 4 (2026)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/

Abstract

Background: Tuberculosis (TB) remains a major health problem, particularly in Indonesia. Early diagnosis of drug-sensitive (DS-TB) and drug-resistant tuberculosis (DR-TB) remains challenging due to limited access to molecular diagnostics in peripheral healthcare settings and difficulties in sputum specimen collection. This study evaluated serum soluble CD163 (sCD163) and monocyte-to-lymphocyte ratio (MLR) for diagnostic utility. Methods: A cross-sectional study included 32 DS-TB patients, 30 DR-TB patients, and 26 healthy controls. Serum sCD163 was measured using ELISA, while MLR was calculated from complete blood counts. Statistical analyses included Kruskal–Wallis, Dunn's post hoc, Spearman correlation, and Cross Tabulation analysis for each comparisons. Results: Both DR-TB and DS-TB showed significantly higher sCD163 levels than controls (p=0.003), with no difference between TB groups (p=0.676). Similarly, MLR was higher in both TB groups than controls (p<0.001), without intergroup differences (p=0.217). Serum sCD163 positively correlated with MLR (r=0.319; p=0.003). Patients with sCD163 >85.97 ng/mL and MLR >0.59 had 1.01-fold and 1.29-fold higher odds of DR-TB, respectively, although these associations were not statistically significant. sCD163 in DR-TB showed slightly lower sCD163 and MLR than DS-TB. This may reflect a more preserved innate immune response with active monocyte–macrophage activation in DS-TB, whereas chronic antigen exposure in DR-TB may induce immune dysregulation and immune exhaustion, reducing monocyte activity and biomarker release. Conclusion: sCD163 and MLR may serve as supportive biomarkers for active TB diagnosis especially DR-TB, with MLR showing greater diagnostic value.